Bignon L, et al. - Analysts assess the pathologic complete response (pCR) rate after neo-adjuvant chemotherapy and aim to compare disease-free survival (DFS) and overall survival (OS) between pCR and non-pCR groups of patients with triple-negative breast cancer (TNBC) and deleterious BRCA1 or BRCA2 mutation. This study demonstrates a high pCR rate after neo-adjuvant therapy in BRCA-mutated triple-negative breast cancer. The survival results affirm the prognostic value of pCR in this group. These results ought to be considered as a basis of comparison to be utilized by future studies about new therapies in this domain.